Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system, will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference. The event will take place on Tuesday, May 20, 2025, at the Nasdaq headquarters in New York City.
The company's Sr. Vice President and CFO, Eyal Rubin, will deliver a presentation and be available for one-on-one meetings with investors. The presentation will be webcast live at 4:30 pm EDT and can be accessed through the company's investor relations website or via the provided webcast link.
Protalix BioTherapeutics (NYSE American: PLX), un'azienda biofarmaceutica specializzata in proteine terapeutiche ricombinanti tramite il suo esclusivo sistema di espressione basato su cellule vegetali ProCellEx®, parteciperà al 3° Annuale H.C. Wainwright BioConnect Investor Conference. L'evento si terrà martedì 20 maggio 2025 presso la sede del Nasdaq a New York City.
Il Senior Vice President e CFO dell'azienda, Eyal Rubin, presenterà un intervento e sarà disponibile per incontri individuali con gli investitori. La presentazione sarà trasmessa in diretta webcast alle 16:30 EDT e sarà accessibile tramite il sito web delle relazioni con gli investitori dell'azienda o tramite il link webcast fornito.
Protalix BioTherapeutics (NYSE American: PLX), una compañía biofarmacéutica especializada en proteínas terapéuticas recombinantes utilizando su sistema exclusivo de expresión basado en células vegetales ProCellEx®, participará en la 3ª Conferencia Anual de Inversores H.C. Wainwright BioConnect. El evento se llevará a cabo el martes 20 de mayo de 2025 en la sede de Nasdaq en la ciudad de Nueva York.
El Vicepresidente Senior y CFO de la compañía, Eyal Rubin, realizará una presentación y estará disponible para reuniones individuales con inversores. La presentación se transmitirá en vivo por webcast a las 4:30 pm EDT y podrá accederse a través del sitio web de relaciones con inversores de la compañía o mediante el enlace de webcast proporcionado.
Protalix BioTherapeutics (NYSE American: PLX)는 독자적인 ProCellEx® 식물 세포 기반 발현 시스템을 사용하여 재조합 치료 단백질을 전문으로 하는 생명공학 회사로, 제3회 연례 H.C. Wainwright BioConnect 투자자 컨퍼런스에 참가합니다. 행사는 2025년 5월 20일 화요일 뉴욕시 나스닥 본사에서 개최됩니다.
회사의 수석 부사장이자 CFO인 에얄 루빈(Eyal Rubin)이 발표를 진행하며 투자자들과 일대일 미팅도 진행할 예정입니다. 발표는 동부 표준시 기준 오후 4시 30분에 생중계되며, 회사 투자자 관계 웹사이트나 제공된 웹캐스트 링크를 통해 접속할 수 있습니다.
Protalix BioTherapeutics (NYSE American : PLX), une société biopharmaceutique spécialisée dans les protéines thérapeutiques recombinantes utilisant son système d'expression propriétaire basé sur des cellules végétales ProCellEx®, participera à la 3e conférence annuelle des investisseurs H.C. Wainwright BioConnect. L'événement aura lieu le mardi 20 mai 2025 au siège du Nasdaq à New York.
Le vice-président principal et directeur financier de la société, Eyal Rubin, fera une présentation et sera disponible pour des réunions individuelles avec les investisseurs. La présentation sera diffusée en direct par webcast à 16h30 EDT et pourra être consultée via le site web des relations investisseurs de la société ou par le lien webcast fourni.
Protalix BioTherapeutics (NYSE American: PLX), ein biopharmazeutisches Unternehmen, das sich auf rekombinante therapeutische Proteine mit seinem proprietären ProCellEx®-Pflanzenzell-Expressionssystem spezialisiert hat, wird an der 3. jährlichen H.C. Wainwright BioConnect Investor Conference teilnehmen. Die Veranstaltung findet am Dienstag, den 20. Mai 2025, im Nasdaq-Hauptquartier in New York City statt.
Der Senior Vice President und CFO des Unternehmens, Eyal Rubin, wird eine Präsentation halten und für Einzelgespräche mit Investoren zur Verfügung stehen. Die Präsentation wird um 16:30 Uhr EDT live per Webcast übertragen und kann über die Investor-Relations-Website des Unternehmens oder den bereitgestellten Webcast-Link abgerufen werden.
- None.
- None.
CARMIEL,
Eyal Rubin, the Company's Sr. Vice President and Chief Financial Officer, will deliver a company presentation and be available for one-on-one investor meetings throughout the event.
Investors interested in scheduling a meeting with the Company's management team should contact their H.C. Wainwright representative or email meetings@hcwco.com.
Event Details
Conference: 3rd Annual H.C. Wainwright BioConnect Investor Conference
Date: Tuesday, May 20, 2025
Location: Nasdaq World Headquarters in
Webcast Details
A webcast of the live presentation will be available at 4:30 pm, Eastern Daylight Time (EDT), via the following links:
Company Link: https://ir.protalix.com/news-events/events
Webcast Link: https://journey.ct.events/view/c15f7813-e688-4a3e-911e-358a9c0562b8
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.
Investor Contact:
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-3rd-annual-hc-wainwright-bioconnect-investor-conference-at-nasdaq-nyc-302455102.html
SOURCE Protalix BioTherapeutics, Inc.
FAQ
When is Protalix BioTherapeutics (PLX) presenting at the H.C. Wainwright Conference?
Who will represent Protalix BioTherapeutics (PLX) at the H.C. Wainwright Conference?
How can investors access Protalix BioTherapeutics' (PLX) presentation at the conference?
How can investors schedule meetings with Protalix BioTherapeutics' (PLX) management?
